OYAH INGREDIENT LIBRARY

Huperzine A

Huperzine A is pharmacologically active. Most evidence involves cognitive disorders, and findings should not be translated into routine nootropic claims.

Evidence reviewUpdated 11 October 2026
HAcetylcholinesterase inhibitor / botanical alkaloid
Evidence signalLow-certainty clinical evidence; limited healthy-adult data
Research focusDementia, mild cognitive impairment and safety
Key qualifierClinical population and drug-like activity

What it is

Huperzine A is an alkaloid isolated from clubmoss species and inhibits acetylcholinesterase. That pharmacology also raises interaction and tolerability concerns.

What human research suggests

Reviews in Alzheimer’s disease or other clinical groups report possible cognitive effects, but study quality, reporting and bias limit confidence. A Cochrane review found no eligible placebo-controlled trials for mild cognitive impairment. Evidence does not establish improved cognition in healthy adults.

HOW THIS RELATES TO OYAH

Huperzine A in an OYAH formula.

The related product page shows the current ingredient list and directions. Compare those details with each paper before deciding how closely the evidence applies. OYAH does not claim that the finished formula was tested in the linked studies.

Cognitive PerformanceView Cognitive Performance
Ingredient studyTests a defined ingredient, preparation and protocol.Finished-product evidenceWould require a clinical trial of the complete formula.Certificate of AnalysisReports the tests shown for a sample or lot; it does not establish benefit.
SAFETY & CONTEXT

What to consider before use.

Possible cholinergic effects include nausea, sweating, slow heart rate, vivid dreams and muscle symptoms. Avoid combining it with acetylcholinesterase inhibitors or other cholinergic products without clinical advice. Heart-rhythm, seizure, lung, gastrointestinal and urinary conditions need added caution.

This guide is educational and is not medical advice. Speak with a qualified healthcare professional about pregnancy, breastfeeding, medical conditions, medicines, surgery or persistent symptoms.

READ THE SOURCES

Follow the evidence.

Each link opens the publication, indexed record or government guidance. Study findings remain limited to the preparation and protocol researchers examined.

  1. Huperzine A evidence overview2021 overview of systematic reviews · PMID 33851462 ↗
  2. Huperzine A for Alzheimer’s disease2013 systematic review and meta-analysis · PMID 24086396 ↗
  3. Huperzine A for mild cognitive impairmentCochrane review · PMID 23235666 ↗
  4. Dementia trials meta-analysis2014 meta-analysis · PMID 24639880 ↗
Current product directory

Know the product. Read the evidence.

Compare the current OYAH range, then open the product-specific evidence and ingredient guides. Ingredient studies do not establish the benefits of a finished OYAH formula.